Sanofi Diabetes
Pay No More Than $25 on up to 12 Lantus® SoloSTAR® pen prescriptions and get ongoing support. Certain restrictions apply. Learn more >>
For U.S. Residents Only
A A A

Change font size  A A A Email Print Prescribing Information Site Map

Close

Lantus® is a once-daily, long-acting insulin that provides 24-hour basal
coverage with no pronounced peak.1

How Lantus® Works Lantus® Efficacy Lantus® Safety Lantus®
SoloSTAR® Pen
View video
  1. Lantus® Prescribing Information. October 2013.
Close

Dosing guidelines and titration for Lantus®

Dosing Titration
Interactive dosing calculator Titration options
Close

Education is an important part of prescribing insulin therapy to help manage
patients' concerns about insulin use.

Therapy Considerations Initiating Treatment Improving Self-Management
Stepwise Approach
Close

Provide educational support for your patients with type 2 diabetes.
Help them understand, know what to expect, and become active participants in their own care.

Day by Day Guide Explaining Diabetes to Patients Getting Patients Started Improving Patient
Self-Care Skills
Useful guides to reinforce your conversations with patients
Close

There are a variety of ways Sanofi can help your patients access their insulin therapy.

Formulary Tool Patient Assistance Savings Offer
Save on Lantus® SoloSTAR®

* Certain eligibility restrictions apply

Close

Tools, links, and educational materials to help you support patients move
toward their glycemic goals.

Professional Resources Patient Resources
Educational materials

Lantus® vs Premix

Effective glycemic control achieved with insulin

Reductions in A1C

  • A1C ≤7% was achieved by 49.4% of patients in the Lantus® + OADs group vs 39.0% of patients in the premix 70/30 group (P=0.0596)

Study Design

From Janka.1

Reductions in plasma glucose

  • Target fasting glucose ≤100 mg/dL was achieved by 31.6% of Lantus® + OADs patients vs 15.0% of premix 70/30 patients at the end of the study (P=0.0002)

Safety Results

Safety Results chart

From Janka.1

Lantus® vs Analog Premix

Insulin significantly lowered A1C in patients uncontrolled on OADs

Reductions in A1C

From Raskin.1
BiAsp=Biphasic Insulin Aspart

  • A1C ≤7% was achieved by 66% of patients in the BiAsp 70/30 + OAD(s) group vs 40% of patients in the Lantus® + OAD(s) group (P<0.001)
  • At study end, total daily insulin doses in the Lantus® + OAD(s) group and BiAsp 70/30 + OAD group were 51.3 Units (±26.7 U) and 78.5 Units (±39.5 U), respectively

Study Design

From Raskin.2

Insulin added to OADs lowered fasting, preprandial, and postprandial glucose

Reductions plasma glucose

  • Target FPG (80-110 mg/dL) was achieved by 57% of Lantus® + OAD(s) patients vs 36% of BiAsp 70/30 + OAD(s) patients at the end of the study

Safety Results2

Safety Results chart

aMajor hypoglycemia was an episode with neurological symptoms consistent with hypoglycemia that required assistance and had either a plasma glucose value <56 mg/dL or reversal of symptoms after food intake, glucagon, or intravenous glucose.

  • Use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia. The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Please click here for Full Prescribing Information for Lantus®.

Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

References:

  1. Janka HU, Plewe G, Riddle MC, et al. Diabetes Care. 2005;28(2):254-259.
  2. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Diabetes

Indications and Usage for Lantus® (insulin glargine [rDNA origin] injection)

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection)

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Click here for additional Important Safety Information.

  • Indications and Usage for Lantus®

    (insulin glargine [rDNA origin] injection)

    Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

    Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

    Important Safety Information for Lantus®

    (insulin glargine [rDNA origin] injection)

    Contraindications
    Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

    Warnings and Precautions
    Monitor blood glucose in all patients treated with insulin. Modify insulin regimen cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

    Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

    Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

    Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Lantus®, monitor and treat if indicated.

    A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

    Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

    Drug Interactions
    Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

    Adverse Reactions
    Adverse reactions commonly associated with Lantus® include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

    Important Safety Information for Lantus® SoloSTAR®

    Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

    Click here for Full Prescribing Information for Lantus®.

    Click here for information on drug anti-counterfeiting.

Bookmark this page
or add it to your home screen
for quick access